CCS
RDY icon

Crosspoint Capital Strategies’s Dr. Reddy's Laboratories RDY Stock Holding History

Crosspoint Capital Strategies’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,435
Closed -$25K – 650
2015
Q4 		$25K Buy
+2,435
New +$26.7K 0.01% 552

Other funds holding RDY

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Crosspoint Capital Strategies's RDY Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Dr. Reddy's Laboratories (RDY) in Q1 2016, closing a stake of 2,435 shares — an estimated $25K sold.

Crosspoint Capital Strategies first reported a position in RDY in Q4 2015 and held it in 1 quarter. The position peaked at $25K in Q4 2015. 160 funds tracked by Wall St. Rank hold RDY as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Dr. Reddy's Laboratories position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 2,435 Dr. Reddy's Laboratories shares in Q1 2016, an estimated $25K.
  • Crosspoint Capital Strategies first reported a position in Dr. Reddy's Laboratories in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Dr. Reddy's Laboratories position peaked at $25K in Q4 2015.
  • 160 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.